Anebulo Pharmaceuticals, Inc. ANEB
0.24 USD -0.02 (-6.92%)
At closeOct 30, 2026, 4:00 PM EDT
0.38 +0.14 +57.81%
After hours · Oct 30, 4:00 PM ET
0.8699 Day range 0.8699
0.001 52-week range 2.56
- YTD
- -76.04%
- 1 year
- -90.83%
Financial health
Altman Z-Score
-8.89 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 2
Valuation
P/E -5.8×
FY 2020 5y median -5.8× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 4.2×
FY 2020 5y median 7.4× FY 2025
P/FCF -7.7×
FY 2020 5y median -8.6× FY 2025
EV/EBITDA -4.8×
FY 2020 5y median -4.8× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -13.0%
FY 2020 5y median -11.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -72.8%
FY 2020 5y median -110.7% FY 2025
ROIC -77.4%
FY 2020 5y median -77.4% FY 2025
ROA -69.9%
FY 2020 5y median -100.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -11.0%
FY 2020 FY 2025
EPS (diluted) 21.9%
FY 2020 FY 2025
Free Cash Flow 21.5%
FY 2020 FY 2025
Financial Health
Current Ratio 53.4×
FY 2020 5y median 30.4× FY 2025
Quick Ratio 53.4×
FY 2020 5y median 30.4× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.5×
FY 2020 5y median 1.0× FY 2025
Interest Coverage -24.1×
FY 2020 5y median -24.1× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-06-30